Drug evaluation: Vildagliptin-metformin single-tablet combination

Advances in Therapy

Volumn 26, Issue 2, 2009, Pages 138-154

  Tahrani, Abd A ^a   Piya, Milan K ^b   Barnett, Anthony H ^b  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

DPP 4 inhibitor; Glycemic control; Metformin; Single tablet combination; Type 2 diabetes; Vildagliptin

Indexed keywords

GLIMEPIRIDE; INSULIN; METFORMIN; METFORMIN PLUS VILDAGLIPTIN; PIOGLITAZONE; PLACEBO; SULFONYLUREA; THIAZOLIDINE DERIVATIVE; TRIACYLGLYCEROL; VILDAGLIPTIN;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; BODY WEIGHT; CLINICAL TRIAL; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FLU LIKE SYNDROME; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN SENSITIVITY; LONG TERM CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; WEIGHT REDUCTION;

ADAMANTANE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG COMBINATIONS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN RESISTANCE; LIPIDS; METFORMIN; NITRILES; PRACTICE GUIDELINES AS TOPIC; PYRROLIDINES; SAFETY; TREATMENT OUTCOME;

EID: 73449128288     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-009-0010-0     Document Type: Review

References (64)

1. International Diabetes Federation. Diabetes Atlas. 3rd edition. Brussels, Belgium: International Diabetes Federation; 2006.
2. M.B. Schulze F.B. Hu 2005 Primary prevention of diabetes: what can be done and how much can be prevented? Annu Rev Public Health 26 445 467 15760297 10.1146/annurev.publhealth.26.021304.144532 (Pubitemid 40547392)
3. K.M. Fox R.A. Gerber Pharmd B. Bolinder J. Chen S. Kumar 2006 Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: a series of retrospective analyses of data from 1998 through 2002 Clin Ther 28 388 395 16750453 10.1016/j.clinthera.2006.03.005 (Pubitemid 44208781)
4. N. Yurgin K. Secnik M.J. Lage 2007 Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study Clin. Ther. 29 316 325 17472823 10.1016/j.clinthera.2007.02.012 1:CAS:528:DC%2BD2sXks1Glur4%3D (Pubitemid 46661861)
5. S. Del Prato A.M. Felton N. Munro 2005 Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Recommendations from the Global Partnership for Effective Diabetes Management Int J Clin Pract. 59 1345 1355 16236091 10.1111/j.1742-1241.2005.00674.x (Pubitemid 43916218)
6. National Institute for Health and Clinical Excellence (NICE). Type 2 diabetes: the management of type 2 diabetes (update). Available at: www.nice.org.uk/CG66. Accessed December 2008.
7. D.M. Nathan J.B. Buse M.B. Davidson 2009 Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 193 203 18945920 10.2337/dc08-9025 1:CAS:528:DC%2BD1MXhs1Gns78%3D
8. J.B. Brown G.A. Nichols A. Perry 2004 The burden of treatment failure in type 2 diabetes Diabetes Care 27 1535 1540 15220224 10.2337/diacare.27.7.1535 (Pubitemid 38857422)
9. UK Prospective Diabetes Study Group. 1998 United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy Ann Intern Med. 128 165 175
10. UK Prospective Diabetes Study 1998 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 837 853 10.1016/S0140-6736(98)07019-6 (Pubitemid 28416718)
11. R.C. Turner C.A. Cull V. Frighi R.R. Holman 1999 Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group JAMA 281 2005 2012 10359389 10.1001/jama.281.21.2005 1:CAS:528:DyaK1MXjvFOls7g%3D (Pubitemid 29254858)
12. D.M. Nathan J.B. Buse M.B. Davidson 2006 Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetologia 49 1711 1721 16802130 10.1007/s00125-006-0316-2 1:STN:280:DC%2BD28vgslygtw%3D%3D (Pubitemid 44025023)
13. A.H. Barnett 2009 New treatments in type 2 diabetes - a focus on the incretin-based therapies Clin Endocrinol 70 343 353 10.1111/j.1365-2265.2008. 03396.x
14. D.J. Drucker M.A. Nauck 2006 The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 1696 1705 17098089 10.1016/S0140-6736(06)69705-5 1:CAS:528: DC%2BD28XhtF2gurjM (Pubitemid 46048557)
15. Novartis. Eucreas. Summary of Product Characteristics (UK). Available at: emc.medicines.org.uk/medicine/20735/SPC/Eucreas+50+mg+850+mg+an d+50+mg+1000+mg+film-coated+tablets/. Accessed February 2009.
16. S. Halimi A. Schweizer B. Minic J. Foley S. Dejager 2008 Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet Vasc Health Risk Manag 4 481 492 18827867 1:CAS:528:DC%2BD1cXpt1ajtbg%3D
17. National Institute for Health and Clinical Excellence (NICE). Type 2 Diabetes: Newer Agents for Blood Glucose Control in Type 2 Diabetes. Full guideline. Draft for consultation. October 2008. Available at: www.nice.org.uk/nicemedia/pdf/T2DDraftGudeline. pdf. Accessed February 2009.
18. M.G. Wulffelé A. Kooy D. de Zeeuw C.D. Stehouwer R.T. Gansevoort 2004 The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review J Intern Med 256 1 14 15189360 10.1111/j.1365-2796.2004.01328.x (Pubitemid 38813614)
19. UK Prospective Diabetes Study 1998 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 854 865 10.1016/S0140-6736(98)07037-8 (Pubitemid 28416719)
20. Novartis. Galvus. Summary of Product Characterisitics (UK). Available at: emc.medicines.org.uk/medicine/20734/SPC/Galvus+50+mg+Tablets/. Accessed February 2009.
21. A. Mari W.M. Sallas Y.L. He 2005 Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves modelassessed beta-cell function in patients with type 2 diabetes J Clin Endocrinol Metab 90 4888 4894 15886245 10.1210/jc.2004-2460 1:CAS:528:DC%2BD2MXnvVWksL0%3D (Pubitemid 41159387)
22. C.A. Abbott D.M. Yu E. Woollatt 2000 Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8 Eur J Biochem 267 6140 6150 11012666 10.1046/j.1432-1327.2000.01617.x 1:CAS:528:DC%2BD3cXnsVygsLk%3D (Pubitemid 30775309)
23. C. Olsen N. Wagtmann 2002 Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV Gene 299 185 193 12459266 10.1016/S0378-1119(02)01059-4 1:CAS:528:DC%2BD38XovFSks7s%3D (Pubitemid 35379840)
24. C.J. Bailey R.C. Turner 1996 Metformin N Engl J Med 334 574 579 8569826 10.1056/NEJM199602293340906 1:CAS:528:DyaK28XhvVCjs74%3D (Pubitemid 26066132)
25. S.M. Setter J.L. Iltz J. Thams R.K. Campbell 2003 Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy Clin Ther 25 2991 3026 14749143 10.1016/S0149-2918(03)90089-0 1:CAS:528:DC%2BD2cXhsVSnsrs%3D (Pubitemid 38096142)
26. A.A. Tahrani G.I. Varughese J.H. Scarpello F.W. Hanna 2007 Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ 335 508 512 17823192 10.1136/bmj.39255.669444.AE 1:CAS:528:DC%2BD2sXhtFOntr%2FF (Pubitemid 47401613)
27. M. Bodmer C. Meier S. Krähenbühl S.S. Jick C.R. Meier 2008 Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis Diabetes Care 31 2086 2091 18782901 10.2337/dc08-1171 1:CAS:528:DC%2BD1cXhsVeqsLzL
28. E. Mannucci E. Pierazzuoli A. Ognibene 2001 Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects Diabetes Care 24 489 494 11289473 10.2337/diacare.24.3.489 1:CAS:528: DC%2BD3MXit1erur0%3D
29. J.R. Lindsay N.A. Duffy A.M. McKillop 2005 Inhibition of dipeptidyl peptidase IV activity by oral metformin in type-2 diabetes Diabet Med 22 654 657 15842525 10.1111/j.1464-5491.2005.01461.x 1:CAS:528:DC%2BD2MXkslKluro%3D (Pubitemid 40593146)
30. S.A. Hinke K. Kühn-Wache T. Hoffmann R.A. Pederson C.H. McIntosh H.U. Demuth 2002 Metformin effects on dipeptidylpeptidase IV degradation of glucagonlike peptide-1 Biochem Biophys Res Commun 291 1302 1308 11883961 10.1006/bbrc.2002.6607 1:CAS:528:DC%2BD38XhslWnsLY%3D (Pubitemid 34694333)
31. B.E. Dunning M. Ligueros-Saylan D.A. D'Alessio 2006 Differential effects of DPP-4 inhibition on incretin hormone levels in drug-naive and metformintreated patients with type 2 diabetes Diabetologia 49 suppl.1 110
32. J.A. Pospisilik J. Martin T. Doty 2003 Dipeptidyl peptidase IV inhibitor treatment stimulates betacell survival and islet neogenesis in streptozotocininduced diabetic rats Diabetes 52 741 750 12606516 10.2337/diabetes.52.3.741 1:CAS:528:DC%2BD3sXitFajtrc%3D (Pubitemid 36323582)
33. A. Duttaroy F. Voelker K. Merriam 2005 The DPP-4 inhibitor vildagliptin increases pancreatic beta cell neogenesis and decreases apoptosis Diabetes 54 suppl.1 A141
34. B. Ahrén J.E. Foley G. Pacini 2005 Improved mealrelated beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year Diabetes Care 28 1936 1940 16043735 10.2337/diacare.28.8.1936 (Pubitemid 41060966)
35. Charbonnel B, Wu M, Karasik A, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 29:2638-2643.
36. B.J. Goldstein M.N. Feinglos J.K. Lunceford 2007 Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes Diabetes Care 30 1979 1987. 17485570 10.2337/dc07-0627 1:CAS:528:DC%2BD2sXpsleksr8%3D (Pubitemid 47219404)
37. E. Bosi R.P. Camisasca C. Collober E. Rochotte A.J. Garber 2007 Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin Diabetes Care 30 890 895 17277036 10.2337/dc06-1732 1:CAS:528:DC%2BD2sXkvVOgu78%3D (Pubitemid 46556583)
38. P. Kar R.I. Holt 2008 The effect of sulphonylureas on the microvascular and macrovascular complications of diabetes Cardiovasc Drugs Ther 22 207 213 18288596 10.1007/s10557-008-6090-2 1:CAS:528:DC%2BD1cXptVKls7s%3D
39. S.S. Singh N. Manne M. Pal 2008 Synthesis of (S)-1-(2-chloroacetyl) pyrrolidine-2-carbonitrile: a key intermediate for dipeptidyl peptidase IV inhibitors Beilstein J Organic Chem 4 20
40. E.B. Villhauer J.A. Brinkman G.B. Naderi 2003 1-[[(3-Hydroxy-1-adamantyl) amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties J Med Chem 46 2774 2789 12801240 10.1021/jm030091l 1:CAS:528: DC%2BD3sXjvFOiurY%3D (Pubitemid 36702545)
41. Y.L. He D. Serra Y. Wang 2007 Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus Clin Pharmacokinet 46 577 588 17596103 10.2165/00003088-200746070-00003 1:CAS:528:DC%2BD2sXptlGrurg%3D (Pubitemid 47025358)
42. Y.L. He B. Flannery J. Campestrini 2008 Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers Curr Med Res Opin 24 1703 1709 18471347 10.1185/03007990802114070 1:CAS:528:DC%2BD1cXptFSgs74%3D (Pubitemid 351929068)
43. Y.L. He R. Sabo J. Campestrini 2008 The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers Br J Clin Pharmacol 65 338 346 17961192 10.1111/j.1365-2125. 2007.03031.x 1:CAS:528:DC%2BD1cXkvFOrsLg%3D (Pubitemid 351316915)
44. European Medicines Association. Eucreas, vildagliptin/metformin hydrochloride. Available at: www.emea.europa.eu/humandocs/PDFs/EPAR/eucreas/H- 807-en6.pdf. Accessed December 2008.
45. B. Ahrén M. Landin-Olsson P.A. Jansson 2004 Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagons levels in type 2 diabetes J Clin Endocrinol Metab 89 2078 2084 15126524 10.1210/jc.2003-031907 (Pubitemid 38619835)
46. B. Balas M.R. Baig C. Watson 2007 The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients J Clin Endocrinol Metab 92 1249 1255 17244786 10.1210/jc.2006-1882 1:CAS:528: DC%2BD2sXksVSrsbw%3D (Pubitemid 46556394)
47. Y.L. He B.M. Sadler R. Sabo 2007 The absolute oral bioavailability and population-based pharmacokinetic modeling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers Clin Pharmacokinet 46 787 802 17713976 10.2165/00003088-200746090-00006 1:CAS:528:DC%2BD2sXhtFyqt7%2FO (Pubitemid 47347450)
48. R.E. Pratley A. Salsali G. Matfin 2006 Inhibition of dipeptidyl peptidase-4 with vildagliptin: a potential new treatment for type 2 diabetes Br J Diabetes Vasc Dis 6 150 156 10.1177/14746514060060040201 1:CAS:528: DC%2BD28XpvFaqurs%3D
49. Y.L. He S. Paladini H. Sabia 2008 Bioequivalence of vildagliptin/ metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects Int J Clin Pharmacol Ther 46 259 267 18538112 1:CAS:528:DC%2BD1cXns1KnsrY%3D
50. Merck Sorono. Glucophage. Summary of Product Characterisitics (UK). Available at: emc.medicines. org.uk/document.aspx?documentId=1043. Accessed February 2009.
51. B. Ahrén R. Gomis E. Standl 2004 Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes Diabetes Care 27 2874 2880 15562200 10.2337/diacare.27.12.2874 (Pubitemid 39565052)
52. G. Bolli F. Dotta E. Rochotte S.E. Cohen 2008 Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study Diabetes Obes Metab. 10 82 90 18034842 1:CAS:528: DC%2BD1cXislCrsrY%3D
53. E. Ferrannini V. Fonseca B. Zinman 2009 Fiftytwo-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy Diabetes Obes Metab. 11 157 166 19125777 10.1111/j.1463-1326.2008.00994.x 1:CAS:528:DC%2BD1MXivVWjtLk%3D
54. R. Braceras L. Blonde M. Banerji 2008 Vildagliptin is as effective as TZDs in metformin failures: results of GALIANT - a primary care diabetes study Diabetologia 51 suppl.1 S366
55. I. Brandt J. Joossens X. Chen 2005 Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl) amino]acetyl}-pyrrolidine-2-carbonitrile) Biochem Pharmacol. 70 134 143 15907807 10.1016/j.bcp.2005.04.009 1:CAS:528:DC%2BD2MXltFCluro%3D (Pubitemid 40797877)
56. B. Richter E. Bandeira-Echtler K. Bergerhoff C. Lerch 2008 Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes Vasc Health Risk Manag 4 753 768 19065993 1:CAS:528:DC%2BD1cXht1Shur%2FI
57. A.M. Lambeir C. Durinx S. Scharpe I. De Meester 2003 Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV Crit Rev Clin Lab Sci. 40 209 294 12892317 10.1080/713609354 1:CAS:528:DC%2BD3sXmtVWhs70%3D
58. N.H. Dang C. Morimoto 2002 CD26: an expanding role in immune regulation and cancer Histol Histopathol. 17 1213 1226 12371149 1:CAS:528: DC%2BD38XptFWmt7Y%3D
59. D.J. Drucker 2007 Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action Diabetes Care 30 1335 1343 17337495 10.2337/dc07-0228 1:CAS:528:DC%2BD2sXntlWksLw%3D (Pubitemid 46871135)
60. B. Richter E. Bandeira-Echtler K. Bergerhoff C.L. Lerch 2008 Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus Cochrane Database Syst Rev 2 CD006739 18425967
61. B. Göke K. Hershon D. Kerr 2008 Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin Horm Metab Res 40 892 895 18726829 10.1055/s-0028-1082334
62. Novartis. Eucreas, a single-tablet combination of Galvus and metformin, set for launch in first EU countries [press release]. Available at: www.prdomain. com/companies/N/Novartis/newsreleases/200822653863.htm. Accessed December 2008.
63. S. Dejager A. Schweizer A. Couturier R.E. Pratley 2007 Achievement of glycaemic targets with vildagliptin Diabetologia 50 suppl.1 S365
64. C. Melikian T.J. White A. Vanderplas C.M. Dezii E. Chang 2002 Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixeddose combination therapy Clin Ther 24 460 467 11952029 10.1016/S0149-2918(02)85047-0 (Pubitemid 34275867)